Biosimilar Antibodies

The Anti-CD24 Antibody (SWA11) is a human IgG1 monoclonal antibody specifically designed to target CD24, a cell surface protein involved in the regulation of cell proliferation and differentiation. This antibody has demonstrated potential anticancer effects, particularly in models of lung and ovarian cancer, making it a valuable tool for oncological research and therapeutic development. For accurate experimental control, it is recommended to use Human IgG1 kappa, Isotype Control.

Reslizumab (Sch 55700) is a humanized monoclonal antibody designed to specifically target and neutralize interleukin-5 (IL-5), a key cytokine involved in the pathogenesis of eosinophilic asthma. This antibody exhibits a high binding affinity for human IL-5, demonstrating dissociation constants (K_D) of 109 pM and 4.3 pM in Biacore surface plasmon resonance and Kinetic Exclusion Assay analyses, respectively. By inhibiting the activity of IL-5, Reslizumab effectively reduces the growth and survival of eosinophils, thereby mitigating the inflammatory processes associated with eosinophilic asthma. This makes Reslizumab a critical tool in the therapeutic management of this condition.

Cilgavimab (AZD-1061; COV2-2130) is a human monoclonal antibody designed to neutralize SARS-CoV-2. When combined with Tixagevimab, it forms the monoclonal antibody cocktail AZD7442. Demonstrating protective efficacy in mouse models of SARS-CoV-2 infection, Cilgavimab targets specific viral epitopes, preventing the virus from entering and infecting healthy cells. This antibody is crucial for research focused on the mechanisms of viral neutralization and the development of therapeutic strategies against COVID-19.

AMG-811 is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets interferon-gamma (IFNγ), a key cytokine in the regulation of immune responses. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 145 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Otelixizumab (ChAglyCD3) is a monoclonal antibody targeting the CD3 antigen on human T cells. It is specifically designed for research applications focusing on Type 1 diabetes. This antibody can be instrumental in studies aimed at understanding T cell behavior and the immune response in diabetic pathology.

Botensilimab (AGEN 1181) is a human monoclonal antibody that targets cytotoxic T-lymphocyte antigen 4 (CTLA-4), serving as both an innate and adaptive immune activator. This biologic is specifically designed for use in cancer research, where it facilitates the study of immune checkpoint blockade and its effects on tumor immunity.

The Anti-CD19 Antibody is a humanized monoclonal antibody expressed in Chinese Hamster Ovary (CHO) cells. It specifically targets CD19, a critical marker expressed on B cells, making it an essential tool for research in immunology and oncology. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 145 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

Teneliximab (BMS-224819) is a chimeric monoclonal antibody designed to inhibit the interaction between CD40 and CD40L. This antibody exhibits partial agonist activity, enabling limited signaling through CD40. Additionally, Teneliximab facilitates the depletion of peripheral B cells, making it a valuable tool for research into immune system modulation and potential therapeutic applications targeting B cell-mediated disorders.

ALT-100 (Human IgG4) is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target NAMPT. This antibody is engineered with a hybrid heavy chain comprising both human IgG1 and IgG4 regions, paired with a human kappa light chain. It exhibits a molecular weight of approximately 150 kDa. ALT-100 is applicable in the study of inflammatory and fibrotic diseases, where Human IgG4 (S228P) kappa serves as the appropriate isotype control. For other research applications, Human IgG1 kappa is recommended as the isotype control. This product is essential for researchers focusing on the modulation of NAMPT activity and its implications in various disease states.

The Anti-PDCD1/PD-1/CD279 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the PDCD1/PD-1/CD279 protein. This antibody is constructed with a human IgG4SP heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of approximately 150 kDa. For isotype control purposes, Human IgG4 kappa, Isotype Control is recommended. This antibody serves as a crucial tool in the study of immune checkpoint regulation and has potential applications in immunotherapy research.

TTX-030 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting ENTPD1/CD39. This antibody is comprised of a human IgG4SP heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of 150 kDa. For isotype control purposes, Human IgG4 kappa, Isotype Control is recommended. TTX-030 is designed for the detailed study of CD39 activity and its role in immunoregulation, making it an essential tool for research in immunology and cancer biology.

Alextatug is a human IgG1 λ7 monoclonal antibody targeting PABPC1. This antibody exhibits high specificity and affinity for the poly(A)-binding protein cytoplasmic 1 (PABPC1), a key regulator in mRNA stabilization and translation. Alextatug is designed for use in research applications to study mRNA processing and regulation mechanisms.

Zinlirvimab is a human IgG1-λ2 monoclonal antibody designed for the neutralization of HIV-1. It specifically targets the gp120 envelope glycoprotein, focusing on the IIIB gp120 V3 loop. This antibody is utilized in research to study the mechanisms of HIV entry into cells and to develop strategies for blocking this process. Zinlirvimab's high specificity and binding affinity make it an essential tool for advanced HIV research and therapeutic development.

Sirukumab (CNTO-136) is a humanized monoclonal IgG1κ antibody targeting IL-6 (Interleukin-6). By binding to IL-6, Sirukumab inhibits IL-6-mediated signal transduction, effectively preventing the activation of transcriptional activators involved in inflammatory responses. This blockade curtails the downstream biological effects associated with IL-6 activity. Sirukumab is primarily utilized in research focused on active lupus nephritis and rheumatoid arthritis, offering significant insights into the pathophysiology and potential therapeutic interventions for these conditions.

The Anti-TPBG Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the TPBG protein, making it a valuable tool for research into its biological functions and involvement in various cellular processes. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 145.8 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control is recommended.

Elgemtumab (LJM716) is a fully human IgG monoclonal antibody designed to selectively target and bind to human epidermal growth factor receptor 3 (HER3). By binding to HER3, Elgemtumab effectively blocks both ligand-dependent and independent signal transduction pathways, thereby inhibiting cellular proliferation. This targeted mechanism demonstrates significant potential in anti-tumor therapies, making it a valuable tool for oncological research and therapeutic development.

Rontalizumab is a humanized IgG1 monoclonal antibody that specifically targets interferon-alpha (IFN-α). This antibody is utilized primarily in research focused on systemic lupus erythematosus, aiding in the exploration of therapeutic avenues and mechanistic insights into the disease.

Cibisatamab is a T cell bispecific antibody designed to simultaneously engage Carcino-Embryonic Antigen (CEA) present on the surface of cancer cells and the CD3 receptor on T cells. This dual binding capability facilitates the targeted destruction of cancer cells exhibiting moderate to high expression of CEA. Primarily utilized in the study of colorectal cancer, Cibisatamab is instrumental in advancing research focused on immune-mediated cancer cell eradication.

Procizumab (AK-1967) is a humanized IgG1 monoclonal antibody specifically targeting dipeptidyl peptidase 3 (DPP3). This antibody is of particular interest for research into the pathophysiology and potential treatments of sepsis. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Mepolizumab (SB 240563) is a humanized monoclonal antibody designed to specifically bind to and neutralize interleukin-5 (IL-5). IL-5 is a critical cytokine that regulates eosinophil proliferation, activation, and survival. This antibody is utilized in research focused on eosinophilic conditions, including eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma, providing a valuable tool for investigating the pathophysiology and potential therapeutic interventions for these diseases.

The Anti-CD11a/LFA-1α Antibody (R7-1) is a chimeric mouse IgG1 monoclonal antibody that specifically targets human CD11a/LFA-1α. For accurate isotype control in experimental procedures, it is recommended to use Mouse IgG1 kappa as the isotype control. This antibody is essential for studies focusing on immune cell adhesion and migration, making it a valuable tool for immunology research.

Anti-LIF Antibody (MSC-1) is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets leukemia inhibitory factor (LIF), a key player in regulating cell differentiation, proliferation, and survival. The antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with a total predicted molecular weight of 146.6 kDa. For isotype control experiments, Human IgG1 kappa, Isotype Control is recommended. This product is ideal for use in research applications focusing on developmental biology, cancer research, and regenerative medicine.

Ivuxolimab is a monoclonal antibody that acts as an agonist to OX40, also identified as CD134 or TNFRSF4. This costimulatory receptor is predominantly expressed on activated CD4+ and CD8+ T cells. The antibody is designed to enhance immune responses and has demonstrated significant antitumor activity, suggesting its utility in immunotherapy applications.

The Anti-CD19 Antibody (4G7) is a chimeric mouse IgG1 monoclonal antibody that specifically targets human CD19. This antibody serves as an essential tool for the identification and characterization of B-cells across various research applications. For isotype control, it is recommended to use Mouse IgG1 kappa, Isotype Control, to ensure specificity and accuracy in experiments involving this antibody.

Clivatuzumab is a humanized monoclonal antibody that specifically targets an epitope on the MUC1 antigen, which is predominantly expressed in pancreatic cancer cells. This antibody is designed to bind selectively to the MUC1 antigen, offering a targeted therapeutic approach predominantly used in the research and treatment of pancreatic cancer.

Amlitelimab is a monoclonal antibody targeting the OX40 Ligand (OX40L). By inhibiting the interaction between OX40 and OX40L, Amlitelimab serves as a valuable tool in the study of atopic dermatitis. This antibody's specificity for OX40L makes it ideal for research applications focused on elucidating the role of this ligand-receptor interaction in immune responses and inflammation associated with dermatological disorders.

Ozureprubart is a humanized IgG1κ monoclonal antibody specifically targeting IGHE. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

GSK-1070806 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target interleukin-18 (IL-18). This antibody is comprised of a human immunoglobulin G1 (huIgG1) heavy chain and a human kappa (huκ) light chain, with a predicted molecular weight of 147.38 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa, Isotype Control. GSK-1070806 serves as a valuable tool for the study of IL-18's role in inflammatory responses and immune regulation, making it applicable in research focused on autoimmune diseases and cytokine regulation.

Lomtegovimab (BI 767551) is a human monoclonal antibody that targets the spike glycoprotein of SARS-CoV-2. This antibody binds to the spike protein, effectively neutralizing the virus and demonstrating significant antiviral efficacy. Lomtegovimab is primarily utilized in research focused on the treatment and understanding of COVID-19. Its specific interaction with the SARS-CoV-2 virus makes it a valuable tool for studies aimed at virus neutralization and therapeutic intervention.

Dapirolizumab is a monoclonal antibody specifically designed to target and bind to CD40 ligand (CD40L), effectively blocking its interaction with CD40 receptors on the surface of immune cells. This interaction is crucial for the activation of the adaptive immune response. By inhibiting this pathway, Dapirolizumab helps to modulate immune system activity and has been shown to attenuate the symptoms of systemic lupus erythematosus. This antibody is applicable in research focused on the pathogenesis and treatment of autoimmune diseases, particularly those involving aberrant CD40-CD40L signaling.

Monalizumab (IPH2201) is a humanized monoclonal antibody designed to inhibit the immune checkpoint receptor Natural Killer Group 2A (NKG2A). By blocking NKG2A, Monalizumab enhances interferon-gamma (IFN-γ) production, which in turn augments the effector functions of natural killer (NK) cells. This antibody is primarily utilized in research focused on understanding and treating head and neck squamous cell carcinoma (HNSCC).

Omectatug is a humanized IgG1κ monoclonal antibody specifically targeting CLDN18. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

Zilovertamab (UC-961) is a humanized monoclonal antibody specifically targeting ROR1. It effectively inhibits Wnt5a-induced ROR1 signaling, a pathway implicated in various oncogenic processes. This antibody serves as a critical tool for research into the role of ROR1 in cancer biology and potential therapeutic interventions.

Vilobelimab (CaCP-29, IFX-1) is a monoclonal antibody specifically targeting C5a, a potent pro-inflammatory peptide derived from the complement system. By binding to C5a, Vilobelimab effectively inhibits its interaction with the C5a receptor, thereby attenuating neutrophil activation and chemotaxis. This inhibition plays a crucial role in reducing inflammatory signaling pathways associated with severe clinical conditions such as organ dysfunction. Vilobelimab is highly relevant for research in pathological states where the complement cascade contributes to disease progression, including sepsis and COVID-19.

The Anti-DLL3 Antibody is derived from the anti-DLL3 arm of Tarlatamab (AMG-757), a bispecific T-cell engager (BiTE) that simultaneously targets DLL3 on tumor cells and CD3 on T cells. This monoclonal antibody is designed for precision in targeting the Delta-like ligand 3 (DLL3) protein, a promising therapeutic target in neuroendocrine tumors, including small cell lung cancer. The antibody's specificity for DLL3 makes it an invaluable tool for research focused on cancer biology and the development of targeted cancer therapies.

Armocibart is a human monoclonal antibody of the IgG4κ subtype designed to target Tissue Factor Pathway Inhibitor (TFPI). For experimental controls, it is recommended to use Human IgG4 (S228P) kappa as an isotype control.

Reflocibart is a human IgG4 κ monoclonal antibody targeting VEGFB. For accurate experimental controls, it is recommended to use Human IgG4 (S228P) kappa as an isotype control.

Orticumab (MLDL1278A) is a monoclonal antibody designed to target and inhibit oxidized or malondialdehyde-modified low-density lipoprotein (oxLDL). This antibody plays a crucial role in modulating autoimmune responses against oxLDL, which is implicated in the pathogenesis of atherosclerosis. Studies have demonstrated that Orticumab effectively improves atherosclerotic conditions in animal models. Additionally, it holds potential for research applications in exploring therapeutic avenues for psoriasis improvement. This antibody's specificity for oxLDL makes it a valuable tool in cardiovascular and autoimmune disease research.

Vanucizumab is a pioneering bispecific IgG1-like monoclonal antibody designed to concurrently inhibit the interaction of vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2) with their respective receptors. This dual blockade mechanism endows vanucizumab with potent antiangiogenic and anticancer properties, making it an essential tool for research in tumor growth and metastasis inhibition.

Enokizumab (MEDI-528) is a monoclonal antibody specifically designed to target interleukin-9 (IL-9). IL-9 plays a critical role in regulating various pathological processes in the respiratory system, including airway inflammation, mucus production, airway hyperresponsiveness, and fibrosis. This regulation is primarily mediated through the proliferation and activation of mast cells within the airways. Enokizumab's mechanism of action focuses on neutralizing IL-9, thereby potentially mitigating its effects on these respiratory conditions. This antibody is pivotal for research focused on the pathophysiology of respiratory diseases and the development of targeted therapies.

Resugosbart is a human IgG4 κ monoclonal antibody targeting SOST. For optimal experimental control, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This antibody is designed for precise specificity to SOST, making it an essential tool for research focused on bone density regulation and osteoporosis.

MGD007 is a humanized IgG1 monoclonal antibody that specifically targets GPA33, a cell surface antigen predominantly expressed in gastrointestinal tissues. This antibody is designed for the investigation of metastatic colorectal cancer, providing a critical tool for researchers studying the pathophysiology and potential therapeutic interventions for this disease. MGD007's specificity to GPA33 makes it an essential reagent for detailed cellular and molecular analysis in colorectal cancer research.

Lecanemab (Mouse IgG2a) is a monoclonal antibody engineered to target soluble β-amyloid, a key player in the pathogenesis of Alzheimer's disease. This antibody is designed to mitigate cognitive decline by interacting with β-amyloid peptides. The variable region of Lecanemab (Mouse IgG2a) mirrors that of the original Lecanemab, ensuring specificity and efficacy in targeting, while its constant region is derived from the Mouse IgG2a sequence, facilitating its use in various experimental setups. Lecanemab (Mouse IgG2a) is an invaluable tool for advancing Alzheimer's disease research, offering potential insights into disease mechanisms and therapeutic interventions.

Vesencumab (MNRP-1685A) is an IgG1 monoclonal antibody that targets neuropilin-1 (NRP-1), a co-receptor involved in angiogenesis and the enhancement of vascular endothelial growth factor (VEGF) signaling through its association with VEGFR-2. By binding to NRP-1, Vesencumab effectively inhibits the interaction between NRP-1 and VEGFR-2, thereby exerting anti-angiogenic and anti-neoplastic effects. This antibody is particularly useful in research focused on the mechanisms of metastasis and tumor growth in solid tumors, including studies on ovarian cancer.

Anti-Ganglioside GD2 Antibody (14G2a) is a chimeric mouse monoclonal antibody of the IgG2a, κ subtype, specifically designed to target human Ganglioside GD2. For accurate experimental control, it is recommended to use Mouse IgG2a kappa as the isotype control. This antibody is pivotal for studies focused on neuronal development, neuroblastoma, and other GD2-related pathologies.